Purpose: To evaluate the efficacy of rose bengal PDAT for the management of a patient with multidrug-resistant Fusarium keratoplasticum keratitis unresponsive to standard clinical treatment.
I
nfectious keratitis secondary to fungal species is a common cause of corneal blindness. There are cases of fungal keratitis that can be successfully treated with standard antifungal agents. Not uncommonly, standard therapy is ineffective and a significant number of patients require a therapeutic graft. Surgical therapy may be curative in many patients; however, chances of graft failure are high and severe complications such as corneal neovascularization, corneal graft rejection, secondary glaucoma, and recurrence of the infection can occur. 1 One alternative treatment for infectious keratitis is collagen cross-linking (CXL), a procedure traditionally used to halt progressive corneal ectasia using riboflavin and UV-A light. One specific category of CXL is photoactivated chromophore CXL; yet, in vitro and in vivo results have demonstrated limited efficacy against fungal species. 2, 3 Given the limitations of photoactivated chromophore CXL to treat fungal keratitis, we investigated rose bengal as an alternative photosensitizer. Rose bengal is a commonly available ocular surface stain activated by green light. In vitro investigations of rose bengal photodynamic antimicrobial therapy (PDAT) have demonstrated inhibition of numerous fungal species. 4 The purpose of this report is to present both in vitro and in vivo efficacy of rose bengal PDAT in multidrug-resistant Fusarium keratitis.
MATERIALS AND METHODS
We performed in vitro susceptibility testing of a patient's fungal isolate against standard antifungals, riboflavin CXL, and rose bengal PDAT. We also report the treatment outcomes (in vivo) of the patient with Fusarium keratitis who received 2 sessions of rose bengal PDAT at Bascom Palmer Eye Institute (BPEI) after obtaining informed consent.
In Vitro
Corneal scrapings were cultured as previously described by Ansari et al. The corneal tissue was scraped with a surgical blade, smeared onto agar plates (chocolate, blood, Sabouraud dextrose, and nonnutrient), and prepared for Gram and Giemsa stains. 5 Only moderate growth of Fusarium species was recovered within 24 hours on multiple media. Molecular sequencing and antifungal susceptibility testing were performed at the Fungus Testing Laboratory, San Antonio, TX. To evaluate susceptibility to rose bengal PDAT and CXL, experiments were performed as previously described by Arboleda et al and Halili et al. 4, 6 In short, the isolate was prepared in suspension in tryptic soy broth and adjusted to a concentration of 5.0 · 10 5 colony-forming units/mL using a Neubauer chamber. Then, 0.1 mL of isolate suspension was mixed with 0.9 mL of either 0.1% photosensitizer solutions. Next, 1 mL was aliquoted onto Sabouraud dextrose plates in triplicate, and plates were exposed to the irradiation source according to experimental group. Irradiation was performed using either a UV-A (l = 375 nm) or a green (l = 518 nm) light source developed at BPEI. Test groups were as follows: 1) control, 2) 0.1% riboflavin: a) dark, b) 30-minute UV-A irradiation, c) 15-minute UV-A irradiation, d) 10-minute UV-A irradiation, and 3) 0.1% rose bengal: a) dark, b) 30-minute green irradiation, c) 15-minute green irradiation, d) 10-minute green irradiation. After irradiation, plates were stored in an incubator for 72 hours and then photographed.
In Vivo
To perform the rose bengal PDAT procedure on the patient, first, a speculum was placed and topical anesthesia (4% lidocaine) was applied to the cornea. The corneal epithelium was debrided in the area of the ulcer. A custom-made shield and well was placed on the cornea, and 0.1% concentration of rose bengal in balanced saline solution was applied in a dropwise manner for 30 minutes. After application of rose bengal, green light was applied for 15 minutes using a custommade green light source. After rose bengal PDAT, the eye was flushed with balanced saline solution.
RESULTS

In Vitro
Molecular sequencing identified the isolate as Fusarium keratoplasticum. Antifungal susceptibility profiles revealed intermediate resistance to natamycin [minimum inhibitory concentration (MIC) 8 mg/mL], and high-level resistance to amphotericin B (MIC 2 mg/mL), voriconazole (MIC 16 FIGURE 1. In vitro results of rose bengal PDAT and riboflavin CXL against F. keratoplasticum. A standard inoculum (10 6 colonyforming units/mL) was used to evaluate the in vitro efficacy of rose bengal PDAT and riboflavin CXL against F. keratoplasticum. Zones of growth inhibition within the irradiated areas were documented for rose bengal PDAT at 72 hours. No zones of inhibition were observed for riboflavin CXL during the same period. A 56-year-old female rigid gas-permeable contact lens wearer, with a history of keratoconus and secondary penetrating keratoplasty 15 years before was referred to BPEI for treatment of possible graft infection. The patient reported good contact lens hygiene and denied sleeping or swimming with contact lenses. At presentation, the patient had a 3.0-3.5 mm corneal defect located in the paracentral-temporal area with associated multiple multifocal infiltrates (,1 mm). Bestcorrected visual acuity was 20/400, and her treatment consisted of hourly topical corticosteroids and polymyxin B sulfate/trimethoprim and fluoroquinolone drops each every 4 hours. Corneal scraping revealed fungal hyphal elements and Fusarium was identified. Treatment with hourly natamycin 5% drops was initiated, and topical corticosteroid was tapered off. Despite compliance for 4 weeks, the corneal infiltrate was no smaller.
At this point, an intrastromal amphotericin B injection (2.25 mg/0.05 mL) was performed and oral fluconazole 400mg daily was initiated. However, despite the intrastromal injection and 3 weeks of oral fluconazole and continued good compliance with hourly natamycin drops, clinical appearance continued to worsen. The patient had progressive corneal thinning (50% depth), +3 graft edema, and the infiltrate was now 5 · 6 mm and threatened the graft-host junction of the temporal area of the cornea, all associated with constant moderate-to-severe pain and severe photophobia.
Given continued worsening and intermediate resistance to multiple antifungal medications, the option of therapeutic penetrating keratoplasty versus experimental rose bengal PDAT were discussed with the patient, and she elected rose bengal PDAT. At day 44, a rose bengal PDAT was performed for a total energy of 0.9 J/cm 2 , as described in the Materials and Methods section (Fig. 2) . Within 36 hours, there was resolution of pain, and over the next 2 weeks, the corneal infiltrate shrank. Four days after treatment, the infiltrate was approximately 1 mm smaller in all directions. At day 57, the infiltrate was almost resolved; at this time, a second session of rose bengal PDAT (1.8 J/cm 2 ) was performed, and all antifungals were discontinued.
On day 86, the corneal epithelial defect and infiltrate resolved. Four weeks later (day 108), the patient began topical steroids. Four months after the first rose bengal PDAT procedure (day 166), corneal scarring and neovascularization decreased, and there was no evidence of any other adverse effects. At latest follow-up (day 290), the patient demonstrated a healthy and quiet ocular surface of the left eye and a clear cornea, which suggests that, in this case, the endothelial function of the graft was unaffected and there is no limbal stem cell deficiency (Fig. 3) .
DISCUSSION
To our knowledge, this is the first patient with fungal keratitis treated with rose bengal PDAT. Initial results are promising; at 6-month follow-up, no recurrence of infection or adverse events had occurred and a therapeutic graft was avoided. In vitro tests showed that the patient's isolate was completely inhibited by rose bengal PDAT. Previous studies showed similar results of antimicrobial efficacy of rose bengal PDAT against a variety of fungal species. 4, 6 The literature reports that riboflavin CXL is less effective against fungal species 2, 3 ; this was also noted in the in vitro experiments performed in this study.
Current standard therapy for fungal keratitis unresponsive to antifungal agents is therapeutic keratoplasty. However, Kirkness et al 1 demonstrated that in 116 therapeutic grafts, 43 failed because of rejection or recurrence of infection with a 5-year survival of 51%. This is in stark contrast to the prognosis of a corneal transplant in eyes with inactive infection, which was comparable to grafts in noninfectious indications, with a 5-year graft survival of 90%. Partial thickness keratoplasty in this patient would be difficult because of the degree of inflammation and secondary tissue necrosis, with a high chance of leaving infected tissue behind and risk of causing iatrogenic perforation. In addition, this would have been this patient's second penetrating keratoplasty, which has reduced graft survival because of the eye having significant neovascularization and inflammation. 7 Rose bengal PDAT has the potential to be a promising treatment for patients with fungal keratitis. However, some factors remain that need further investigation. Laboratory testing has demonstrated a different response to rose bengal PDAT depending on the fungal species. Hence, photosensitizer concentration, irradiation energy, and treatment duration need to be thoughtfully studied and implemented to maximize the benefits of rose bengal PDAT.
Encouraging in vitro results reported by Fadlallah et al showed that rose bengal PDAT has the capability of arresting the corneal melting process, in addition to our in vitro results showing inhibition of growth of microorganisms. 8 Another determining factor of success is penetration of rose bengal into the cornea. Rose bengal, like other photosensitizers, has limited diffusion into the cornea (;100-150 mm). 9 However, in cases of corneal ulceration, the infection itself might allow rose bengal to reach the depth of the microorganisms. A final point of discussion is that the patient may have benefited from administering rose bengal PDAT earlier in the disease course, which could have possibly reduced healing time and infection-related complications.
This case demonstrates proof of principle of the potential of PDAT in the management of resistant infectious keratitis. This patient received aggressive medical treatment, and despite good compliance, her infection continued to progress and worsen. It was not until the rose bengal PDAT treatment that the infection process was halted. This patient was the first we offered this treatment and patient received a low energy treatment; however, since treating this patient, we have found that 5.4 J/cm 2 over 15-minute exposure has provided the most improvement with no complications. Further investigations need to be performed to understand the precise role of rose bengal PDAT in treating fungal keratitis.
